Cracking The Code: Understanding Analyst Reviews For OrthoPediatrics
Portfolio Pulse from Benzinga Insights
OrthoPediatrics (NASDAQ:KIDS) received mixed analyst ratings, with a recent shift towards more bullish views. The average 12-month price target is now $38.2, up from $35.33, indicating an 8.12% increase. Analyst actions include ratings adjustments and price target changes, reflecting updated market conditions and company performance. OrthoPediatrics, a medical device company focused on pediatric orthopedic products, showed a revenue growth of 14.37% for the quarter ending September 30, 2023, but its growth rate is below the Health Care sector average. The company has a notable net margin of -11.49% and an ROE of -1.22%, with a debt-to-equity ratio of 0.0.
March 07, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OrthoPediatrics received more bullish analyst ratings, with an updated average 12-month price target of $38.2, reflecting an 8.12% increase from the previous target. The company's revenue growth and financial metrics were also highlighted.
The increase in the average price target and the shift towards more bullish ratings suggest a positive outlook for OrthoPediatrics' stock in the short term. The company's solid revenue growth and financial metrics, despite being below the Health Care sector average, support this optimism. The detailed analysis by analysts and the company's performance metrics indicate a strong foundation for the positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100